OR-AIRSHIP
16.5.2019 15:02:09 CEST | Business Wire | Press release
Customer engagement company Airship today announced May and June dates and locations for its 2019 Customer Engagement Forum , a year-long global event series. These interactive sessions feature leaders from many of the world's leading brands discussing their plans and practices for customer engagement (CX) in a digital world — arming marketers with proven strategies, research and techniques to connect with customers in smarter, faster, and more effective ways.
Dubbed ELEVATE, the educational series will kick-off in Santa Monica on May 21, 2019 and San Francisco on May 30, 2019. In June, the forum series will come to Paris , Chicago , New York , Amsterdam and London . Seats are limited; those interested in attending should reserve their spot using the city-specific links above. Additional cities and dates will be announced later this year.
Featuring a unique collection of speakers in each city, the series will focus on the growing focus on customer experience (CX) as the key driver of many companies’ growth and competitive strategies. Among topics such as CX best practices and innovation, the program will also include a discussion of building a business case for the value of better customer experience (CX).
According to Gartner, “Today, slightly more than two-thirds of marketers responsible for CX say their companies compete on the basis of CX. In two years, this expectation rises even further, with 81% of respondents anticipating their companies will do so.” (Gartner, Customer Experience in Marketing Survey 2017: Greater Expectations, Greater Challenges, Augie Ray, Jane-Anne Mennella, Simon Yates, Refreshed April 9, 2019, Published 5 October 2017).
Customer Engagement Forum attendees will gain a sharper understanding of what’s at stake when it comes to getting customer engagement right — learning about the CX trends experts are watching, as well as the CX tech stack and common team structures. Beyond a notebook full of ideas to leapfrog the competition and crush their KPIs, attendees will gain stats to build a business case for the value of better CX to grow their budgets and their careers.
“Forrester analyzed the correlation between CX quality and revenue growth for companies in five industries ... companies with superior CX grew revenues five times faster on average than their competitors with inferior CX. And this is a global phenomenon” (Forrester Research, Inc., “Improving CX Through Business Discipline Drives Growth,” June 19, 2017; Updated March 26, 2018).
Companies speaking at Customer Engagement Forum events include AccuWeather, AMC Theatres, Expensify, Footlocker, France TV, GSN Games, Tribune Publishing, Turner Sports and Zillow, with more to come.
“Today’s fastest-growing brands separate themselves from the pack by providing unique experiences that deliver surprising convenience and delight to their customers,” said Mike Stone, SVP of Marketing, Airship. “The Airship Customer Engagement Forum provides marketers an incredible opportunity to learn successful CX strategies from leading brands, as well as the programs and tactics to put them into place.”
For more information on Airship’s Customer Engagement Forum 2019, or to register, please visit forum.airship.com .
About Airship
Marketing and digital experience teams at thousands of the world’s most admired companies rely on Airship’s Customer Engagement Platform to create deeper connections with customers by delivering incredibly relevant, orchestrated messages on any channel.
Founded in 2009 as a pioneer in push notifications, Airship now gives brands the user-level data, engagement channels, AI orchestration and services they need to deliver push notifications, emails, SMS, in-app messages, mobile wallet cards and more to exactly the right person in exactly the right moment — building trust, boosting engagement, driving action and growing value.
Learn more about our Customer Engagement Platform , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005238/en/
Contact:
North America: Dave Struzzi Bateman Group +1 415-697-2560 airship@bateman-group.com
Corey Gault Airship +1 503-206-9164 corey@airship.com
EMEA: Nicolas Vitre Airship +33 1 44 56 88 21 +33 6 88 04 76 86 nicolas.vitre@airship.com
UK: Lucinda Layton Hotwire UK +44 20 7608 2500 Airship@hotwireglobal.com
France: Marion Fajgenbaum / Marine Cressot Hotwire France +33 14 312 55 68 / 69 AirshipFR@hotwireglobal.com
Germany: Julia da Silva Bastos Hotwire Germany +49 89 2620 81 89 airshipde@hotwireglobal.com
Spain: Beatriz Pérez Hotwire Spain +34 917 44 1265 beatriz.perez@hotwireglobal.com
Italy: Sara Tetti Hotwire Italy +39 349 5788052 AirshipIT@hotwireglobal.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom